Vistagen Therapeutics (VTGN) Treasury Shares (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Treasury Shares of $4.0 million for Q1 2026, little changed sequentially from $4.0 million in Q4 2025, and little changed YoY from $4.0 million in Q1 2025.
Vistagen Therapeutics (VTGN) Treasury Shares (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Treasury Shares for 13 years, with the latest figure at $4.0 million in Q1 2026.
- Quarterly Treasury Shares changed 0.0% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (changed 0.0% YoY) and the FY2026 annual result came in at $4.0 million, changed 0.0% from the prior year.
- Treasury Shares was little changed at $4.0 million in Q1 2026 per VTGN's latest filing, from $4.0 million in the prior quarter.
- Over five years, Treasury Shares peaked at $135665.0 in Q2 2022 and troughed at $4522.0 in Q1 2022.
- A 5-year average of $29111.3 and a median of $4522.0 in 2022 frame the typical range for Treasury Shares.
- The sharpest annual moves came in 2022 and 2023: Treasury Shares changed 0.0% in 2022, then dropped 0.0% in 2023.
- Over 5 years, Treasury Shares stood at $4.0 million in 2022, then changed by 0.0% to $4.0 million in 2023, then dropped by 0.0% to $4.0 million in 2024, then changed by 0.0% to $4.0 million in 2025, then changed by 0.0% to $4.0 million in 2026.
- According to Business Quant data, Treasury Shares over the past three periods registered $4.0 million, $4.0 million, and $4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.96 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.72 Mn |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - | 3.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.97 Mn |
| Mar 31, 2026 | 3.97 Mn |
| Mar 31, 2026 | 4,522.00 |
| Mar 31, 2026 | 4,522.00 |
| Dec 31, 2025 | 4,522.00 |
| Dec 31, 2025 | 4,522.00 |
| Dec 31, 2025 | 3.97 Mn |
| Dec 31, 2025 | 3.97 Mn |
| Sep 30, 2025 | 3.97 Mn |
| Sep 30, 2025 | 3.97 Mn |
| Sep 30, 2025 | 4,522.00 |
| Sep 30, 2025 | 4,522.00 |
| Jun 30, 2025 | 3.97 Mn |
| Jun 30, 2025 | 3.97 Mn |
| Jun 30, 2025 | 4,522.00 |
| Jun 30, 2025 | 4,522.00 |
| Mar 31, 2025 | 4,522.00 |
| Mar 31, 2025 | 3.97 Mn |
| Mar 31, 2025 | 3.97 Mn |
| Mar 31, 2025 | 4,522.00 |